Willie A. Deese
Known title: DirectorCIK: 0001328766
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
Transaction History
| PEG | ▲ Buy | Grant | 2,246 | $180K | 5/1/2026 | View on chart |
| XRAY | ▲ Buy | Grant | 202 | $0 | 1/9/2026 | View on chart |
| PEG | ▼ Sell | Gift | 1,000 | $0 | 12/3/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 179 | $0 | 10/10/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 139 | $0 | 7/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 13,880 | $0 | 5/22/2025 | View on chart |
| PEG | ▲ Buy | Grant | 2,289 | $180K | 5/1/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 87 | $0 | 4/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 68 | $0 | 1/10/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 48 | $0 | 10/11/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 51 | $0 | 7/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 7,994 | $0 | 5/23/2024 | View on chart |
| PEG | ▲ Buy | Grant | 2,579 | $180K | 5/1/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 26 | $0 | 4/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 21 | $0 | 1/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 49 | $0 | 10/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 41 | $0 | 7/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 5,419 | $0 | 5/25/2023 | View on chart |
| PEG | ▲ Buy | Grant | 2,851 | $180K | 5/1/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 23 | $0 | 4/15/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 25 | $0 | 1/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 6,382 | $0 | 11/15/2022 | View on chart |
| XRAY | ▲ Buy | Option Exercise | 6,900 | $262K | 5/23/2022 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 6,814 | $262K | 5/23/2022 | View on chart |
| PEG | ▲ Buy | Grant | 2,615 | $180K | 5/2/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 8 | $0 | 4/8/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6 | $0 | 1/14/2022 | View on chart |
| XRAY | ▲ Buy | Grant | 6 | $331 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
PSEG Q3 Earnings Due Nov 2; Truist Cuts Target to $78
Public Service Enterprise Group is set to report its third-quarter financial results on November 2. Ahead of this release, Truist Securities maintained a Hold rating but lowered its price target to $78. The company also published its 2026 Sustainability Report, highlighting ongoing efforts in reliability and community support.
PSEG Q3 Earnings Due Nov 2; Truist Cuts Target to $78. Public Service Enterprise Group is set to report its third-quarter financial results on November 2. Ahead of this release, Truist Securities maintained a Hold rating but lowered its price target to $78. The company also published its 2026 Sustainability Report, highlighting ongoing efforts in reliability and community support.